INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28901, 20325, 'Tranexamic acid', 'Subarachnoid Hemorrhage', 'The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage.  Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28902, 20326, 'Tranexamic acid', 'Subarachnoid Hemorrhage', 'The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage.  Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28903, 20329, 'Tranexamic acid', 'Subarachnoid Hemorrhage', 'The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage.  Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28904, 20330, 'Tranexamic acid', 'Subarachnoid Hemorrhage', 'The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage.  Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28905, 21251, 'Tranexamic acid', 'Subarachnoid Hemorrhage', 'The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage.  Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28906, 21252, 'Tranexamic acid', 'Subarachnoid Hemorrhage', 'The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage.  Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28907, 26563, 'Tranexamic acid', 'Subarachnoid Hemorrhage', 'The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage.  Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28908, 27923, 'Tranexamic acid', 'Subarachnoid Hemorrhage', 'The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage.  Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28909, 28397, 'Tranexamic acid', 'Subarachnoid Hemorrhage', 'The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage.  Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28910, 28447, 'Tranexamic acid', 'Subarachnoid Hemorrhage', 'The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage.  Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28911, 10208, 'Tranexamic acid', 'Color Vision Defects', 'Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances.  Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy.  Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted.  Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months.  Discontinue treatment if changes in ophthalmological examination occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28912, 15363, 'Tranexamic acid', 'Color Vision Defects', 'Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances.  Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy.  Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted.  Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months.  Discontinue treatment if changes in ophthalmological examination occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28913, 17001, 'Tranexamic acid', 'Color Vision Defects', 'Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances.  Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy.  Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted.  Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months.  Discontinue treatment if changes in ophthalmological examination occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28914, 17002, 'Tranexamic acid', 'Color Vision Defects', 'Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances.  Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy.  Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted.  Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months.  Discontinue treatment if changes in ophthalmological examination occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28915, 20325, 'Tranexamic acid', 'Color Vision Defects', 'Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances.  Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy.  Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted.  Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months.  Discontinue treatment if changes in ophthalmological examination occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28916, 20326, 'Tranexamic acid', 'Color Vision Defects', 'Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances.  Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy.  Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted.  Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months.  Discontinue treatment if changes in ophthalmological examination occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28917, 20329, 'Tranexamic acid', 'Color Vision Defects', 'Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances.  Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy.  Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted.  Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months.  Discontinue treatment if changes in ophthalmological examination occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28918, 20330, 'Tranexamic acid', 'Color Vision Defects', 'Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances.  Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy.  Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted.  Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months.  Discontinue treatment if changes in ophthalmological examination occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28919, 21251, 'Tranexamic acid', 'Color Vision Defects', 'Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances.  Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy.  Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted.  Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months.  Discontinue treatment if changes in ophthalmological examination occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28920, 21252, 'Tranexamic acid', 'Color Vision Defects', 'Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances.  Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy.  Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted.  Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months.  Discontinue treatment if changes in ophthalmological examination occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28921, 26563, 'Tranexamic acid', 'Color Vision Defects', 'Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances.  Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy.  Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted.  Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months.  Discontinue treatment if changes in ophthalmological examination occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28922, 27923, 'Tranexamic acid', 'Color Vision Defects', 'Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances.  Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy.  Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted.  Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months.  Discontinue treatment if changes in ophthalmological examination occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28923, 28397, 'Tranexamic acid', 'Color Vision Defects', 'Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances.  Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy.  Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted.  Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months.  Discontinue treatment if changes in ophthalmological examination occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28924, 28447, 'Tranexamic acid', 'Color Vision Defects', 'Tranexamic acid should be used with caution in patients with acquired defective color vision or visual disturbances.  Poorly characterized visual abnormalities have been reported in patients during tranexamic acid therapy.  Retinal degeneration in a variety of animal species (not human) at oral and IV doses 3 to 40 times the recommended human dosage has been noted.  Ophthalmologic testing and monitoring (visual acuity, and optical coherence tomography) prior to and at regular intervals during treatment is recommended for patients treated longer than 3 months.  Discontinue treatment if changes in ophthalmological examination occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28925, 10208, 'Tranexamic acid', 'Seizures', 'Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.  Caution is advised if administering in patients with convulsive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28926, 15363, 'Tranexamic acid', 'Seizures', 'Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.  Caution is advised if administering in patients with convulsive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28927, 17001, 'Tranexamic acid', 'Seizures', 'Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.  Caution is advised if administering in patients with convulsive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28928, 17002, 'Tranexamic acid', 'Seizures', 'Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.  Caution is advised if administering in patients with convulsive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28929, 20325, 'Tranexamic acid', 'Seizures', 'Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.  Caution is advised if administering in patients with convulsive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28930, 20326, 'Tranexamic acid', 'Seizures', 'Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.  Caution is advised if administering in patients with convulsive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28931, 20329, 'Tranexamic acid', 'Seizures', 'Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.  Caution is advised if administering in patients with convulsive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28932, 20330, 'Tranexamic acid', 'Seizures', 'Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.  Caution is advised if administering in patients with convulsive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28933, 21251, 'Tranexamic acid', 'Seizures', 'Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.  Caution is advised if administering in patients with convulsive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28934, 21252, 'Tranexamic acid', 'Seizures', 'Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.  Caution is advised if administering in patients with convulsive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28935, 26563, 'Tranexamic acid', 'Seizures', 'Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.  Caution is advised if administering in patients with convulsive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28936, 27923, 'Tranexamic acid', 'Seizures', 'Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.  Caution is advised if administering in patients with convulsive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28937, 28397, 'Tranexamic acid', 'Seizures', 'Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.  Caution is advised if administering in patients with convulsive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28938, 28447, 'Tranexamic acid', 'Seizures', 'Convulsions have been reported in association with tranexamic acid treatment, particularly in patients receiving tranexamic acid during cardiovascular surgery and in patients inadvertently given tranexamic acid into the neuraxial system.  Caution is advised if administering in patients with convulsive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28939, 10208, 'Tranexamic acid', 'Kidney Diseases', 'Tranexamic acid is primarily eliminated by the kidney.  Approximately 95% of tranexamic acid is excreted in the urine unchanged.  The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment.  Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal  and clotting functions is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28940, 15363, 'Tranexamic acid', 'Kidney Diseases', 'Tranexamic acid is primarily eliminated by the kidney.  Approximately 95% of tranexamic acid is excreted in the urine unchanged.  The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment.  Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal  and clotting functions is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28941, 17001, 'Tranexamic acid', 'Kidney Diseases', 'Tranexamic acid is primarily eliminated by the kidney.  Approximately 95% of tranexamic acid is excreted in the urine unchanged.  The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment.  Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal  and clotting functions is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28942, 17002, 'Tranexamic acid', 'Kidney Diseases', 'Tranexamic acid is primarily eliminated by the kidney.  Approximately 95% of tranexamic acid is excreted in the urine unchanged.  The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment.  Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal  and clotting functions is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28943, 20325, 'Tranexamic acid', 'Kidney Diseases', 'Tranexamic acid is primarily eliminated by the kidney.  Approximately 95% of tranexamic acid is excreted in the urine unchanged.  The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment.  Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal  and clotting functions is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28944, 20326, 'Tranexamic acid', 'Kidney Diseases', 'Tranexamic acid is primarily eliminated by the kidney.  Approximately 95% of tranexamic acid is excreted in the urine unchanged.  The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment.  Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal  and clotting functions is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28945, 20329, 'Tranexamic acid', 'Kidney Diseases', 'Tranexamic acid is primarily eliminated by the kidney.  Approximately 95% of tranexamic acid is excreted in the urine unchanged.  The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment.  Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal  and clotting functions is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28946, 20330, 'Tranexamic acid', 'Kidney Diseases', 'Tranexamic acid is primarily eliminated by the kidney.  Approximately 95% of tranexamic acid is excreted in the urine unchanged.  The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment.  Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal  and clotting functions is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28947, 21251, 'Tranexamic acid', 'Kidney Diseases', 'Tranexamic acid is primarily eliminated by the kidney.  Approximately 95% of tranexamic acid is excreted in the urine unchanged.  The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment.  Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal  and clotting functions is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28948, 21252, 'Tranexamic acid', 'Kidney Diseases', 'Tranexamic acid is primarily eliminated by the kidney.  Approximately 95% of tranexamic acid is excreted in the urine unchanged.  The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment.  Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal  and clotting functions is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28949, 26563, 'Tranexamic acid', 'Kidney Diseases', 'Tranexamic acid is primarily eliminated by the kidney.  Approximately 95% of tranexamic acid is excreted in the urine unchanged.  The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment.  Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal  and clotting functions is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28950, 27923, 'Tranexamic acid', 'Kidney Diseases', 'Tranexamic acid is primarily eliminated by the kidney.  Approximately 95% of tranexamic acid is excreted in the urine unchanged.  The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment.  Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal  and clotting functions is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28951, 28397, 'Tranexamic acid', 'Kidney Diseases', 'Tranexamic acid is primarily eliminated by the kidney.  Approximately 95% of tranexamic acid is excreted in the urine unchanged.  The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment.  Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal  and clotting functions is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28952, 28447, 'Tranexamic acid', 'Kidney Diseases', 'Tranexamic acid is primarily eliminated by the kidney.  Approximately 95% of tranexamic acid is excreted in the urine unchanged.  The serum concentration of tranexamic acid is increased and the elimination half-life prolonged in patients with renal impairment.  Therapy with tranexamic acid should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal  and clotting functions is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28953, 0, 'Treprostinil', 'Hepatic Insufficiency', 'The use of the extended-release tablet formulation of treprostinil is contraindicated in patients with severe hepatic impairment (Child Pugh Class C).  There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients.  It is recommended to start patients with mild hepatic impairment (Child Pugh Class A) at 0.125 mg BID with 0.125 mg BID dose increments every 3 to 4 days and to avoid use of treprostinil in patients with moderate hepatic impairment (Child Pugh Class B).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28954, 0, 'Treprostinil', 'Hemorrhage', 'Treprostinil injection inhibits platelet aggregation and increases the risk of bleeding.  Close monitoring is recommended when using this agent in patients with bleeding disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28955, 0, 'Treprostinil', 'Diverticulum', 'The tablet shell of the manufactured form of treprostinil, Orenitram does not dissolve and can lodge in the diverticulum of patients with diverticulosis.  Care should be exercised when using this drug in patient with diverticulosis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28956, 0, 'Treprostinil', 'Hypotension', 'Treprostinil is a pulmonary and systemic vasodilator.  In patients with low systemic arterial pressure, treatment with treprostinil injection may produce symptomatic hypotension.  Care should be exercised when using this agent in patients at risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28957, 0, 'Treprostinil', 'Liver Diseases', 'Severe hepatic impairment (Child Pugh Class C) is a contraindication in patients taking the oral presentation of treprostinil.  Treprostinil is substantially metabolized by the liver, primarily by CYP450 2C8.  Treprostinil injection clearance is reduced in patients with hepatic insufficiency.  In patients with mild or moderate hepatic insufficiency, decrease the initial dose of treprostinil injection to 0.625 ng/kg/min ideal body weight, and monitor closely.  Treprostinil injection has not been studied in patients with severe hepatic insufficiency.  It is recommended to titrate treprostinil injection slowly in patients with hepatic insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic or renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28958, 0, 'Treprostinil', 'Pneumonia', 'The efficacy of treprostinil inhalant has not been established in patients with significant underlying lung disease.  Patients with acute pulmonary infections should be carefully monitored to detect any worsening of lung disease and loss of drug effect.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28959, 0, 'Treprostinil', 'Kidney Diseases', 'Treprostinil and its metabolites are excreted mainly through the urinary route.  It is recommended to titrate treprostinil injection slowly in patients with renal insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal renal function.  No dose adjustments are required in patients with renal impairment.  Treprostinil is not cleared by dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28960, 6838, 'Triamcinolone (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28961, 6840, 'Triamcinolone (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28962, 11634, 'Triamcinolone (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28963, 23270, 'Triamcinolone (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28964, 28461, 'Triamcinolone (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28965, 6838, 'Triamcinolone (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28966, 6840, 'Triamcinolone (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28967, 11634, 'Triamcinolone (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28968, 23270, 'Triamcinolone (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28969, 28461, 'Triamcinolone (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28970, 6838, 'Triamcinolone (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28971, 6840, 'Triamcinolone (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28972, 11634, 'Triamcinolone (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28973, 23270, 'Triamcinolone (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28974, 28461, 'Triamcinolone (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28975, 6838, 'Triamcinolone (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28976, 6840, 'Triamcinolone (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28977, 11634, 'Triamcinolone (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28978, 23270, 'Triamcinolone (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28979, 28461, 'Triamcinolone (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28980, 481, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28981, 482, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28982, 484, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28983, 2999, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28984, 3000, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28985, 3002, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28986, 3003, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28987, 3004, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28988, 11150, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28989, 11576, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28990, 11578, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28991, 11579, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28992, 11580, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28993, 11581, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28994, 11862, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28995, 11863, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28996, 13885, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28997, 23941, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28998, 23943, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28999, 27880, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29000, 28384, 'Tramadol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
